Trials / Unknown
UnknownNCT04856150
A Study of Q-1802 in Patients With Advanced Solid Tumors
A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Q-1802 in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- QureBio Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Q-1802 is a bispecific antibody targeting both the tumor-specific antigen Claudin 18.2 and the immune checkpoint PD-L1. This is a multi-center, single-arm, open-label design to evaluate the safety and tolerance of Q-1802 in patients with advanced solid tumors, together with an assessment of pharmacokinetic characteristics and efficacy. The study consisted of two compartments: the dose-exploration stage and the dose-extension stage.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Q-1802 | Q-1802 will be administered intravenously. |
Timeline
- Start date
- 2021-05-21
- Primary completion
- 2024-04-01
- Completion
- 2024-07-01
- First posted
- 2021-04-23
- Last updated
- 2023-07-27
Locations
4 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04856150. Inclusion in this directory is not an endorsement.